Strategic Financial Concepts LLC Has $12.37 Million Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Strategic Financial Concepts LLC boosted its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 8,384.4% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 143,810 shares of the company’s stock after buying an additional 142,115 shares during the period. Strategic Financial Concepts LLC’s holdings in Novo Nordisk A/S were worth $12,371,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in the business. Natixis Advisors LLC grew its stake in shares of Novo Nordisk A/S by 2.7% in the third quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock valued at $366,125,000 after buying an additional 80,070 shares in the last quarter. Norman Fields Gottscho Capital Management LLC lifted its holdings in Novo Nordisk A/S by 45.3% during the 4th quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company’s stock valued at $5,482,000 after purchasing an additional 19,870 shares during the last quarter. Versant Capital Management Inc acquired a new stake in Novo Nordisk A/S during the 4th quarter valued at $86,000. Talbot Financial LLC acquired a new stake in Novo Nordisk A/S during the 4th quarter valued at $4,066,000. Finally, Clear Creek Financial Management LLC acquired a new stake in Novo Nordisk A/S during the 4th quarter valued at $450,000. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Trading Down 1.1 %

Shares of Novo Nordisk A/S stock opened at $77.94 on Friday. The stock has a fifty day simple moving average of $88.65 and a 200 day simple moving average of $109.83. Novo Nordisk A/S has a 12-month low of $77.82 and a 12-month high of $148.15. The company has a market capitalization of $349.75 billion, a P/E ratio of 23.69, a price-to-earnings-growth ratio of 0.96 and a beta of 0.45. The company has a current ratio of 0.74, a quick ratio of 0.75 and a debt-to-equity ratio of 0.62.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. On average, sell-side analysts anticipate that Novo Nordisk A/S will post 3.86 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The company also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be issued a dividend of $0.7874 per share. This is a positive change from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. This represents a yield of 1.2%. The ex-dividend date is Monday, March 31st. Novo Nordisk A/S’s dividend payout ratio is currently 21.88%.

Analysts Set New Price Targets

Several equities research analysts have issued reports on NVO shares. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. BMO Capital Markets dropped their target price on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a report on Monday, December 23rd. Morgan Stanley initiated coverage on Novo Nordisk A/S in a report on Wednesday. They set an “equal weight” rating for the company. StockNews.com downgraded Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Novo Nordisk A/S has a consensus rating of “Moderate Buy” and an average price target of $145.25.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.